Anixa Biosciences公布了其研究性乳腺癌疫苗的第一阶段积极数据;所有主要终点均已达成,并且在74%的参与者中观察到免疫反应。
Anixa Biosciences公布了其研究性乳腺癌疫苗的第一阶段积极数据;所有主要终点均已达成,并且在74%的参与者中观察到免疫反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.